This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/drugbank/drug/DB05416/identifier/chemspider/
n10http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/drug/DB05416/identifier/bindingdb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB05416/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB05416/identifier/drugbank/

Statements

Subject Item
n2:DB05416
rdf:type
n3:Drug
n3:description
GW-501516 is a peroxisome proliferator-activator receptor-delta agonist for the potential treatment of dyslipidemia. It is developed by GlaxoSmithKline. This drug is in Phase II clinical trials .
n3:generalReferences
# Dimopoulos N, Watson M, Green C, Hundal HS: The PPARdelta agonist, GW501516, promotes fatty acid oxidation but has no direct effect on glucose utilisation or insulin sensitivity in rat L6 skeletal muscle cells. FEBS Lett. 2007 Oct 2;581(24):4743-8. Epub 2007 Sep 6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17869249 # Kramer DK, Al-Khalili L, Guigas B, Leng Y, Garcia-Roves PM, Krook A: Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. J Biol Chem. 2007 Jul 6;282(27):19313-20. Epub 2007 May 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17500064 # Fredenrich A, Grimaldi PA: PPAR delta: an uncompletely known nuclear receptor. Diabetes Metab. 2005 Feb;31(1):23-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15803109
n3:group
investigational
n3:indication
Investigated for use/treatment in hyperlipidemia.
owl:sameAs
n10:DB05416
dcterms:title
GW 501516
adms:identifier
n6:28661 n7:7979723 n11:DB05416 n12:9803963
n3:mechanismOfAction
This drug regulates fatty acid oxidation in several tissues, such as skeletal muscle and adipose tissue. Overexpression of PPARdelta using a transgenic murine model promotes an increase of muscle oxidative capability. It also plays a major role in the metabolic adaptations to western diet characterized by an excessive amount of saturated fat.
n3:IUPAC-Name
n4:271B4322-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4328-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4327-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4324-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4325-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4326-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4320-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4321-363D-11E5-9242-09173F13E4C5 n4:271B431E-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B431F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B432E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B432F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4329-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B432A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B432C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B432B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B432D-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4334-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4336-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4337-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4333-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4332-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4335-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4323-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4330-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4331-363D-11E5-9242-09173F13E4C5